Loading
T cells taken from patients and engineered to recognise the MAGE-A4 protein shrank tumours in about four in ten patients with advanced synovial sarcoma, leading to the first approval of a TCR T-cell therapy for any solid cancer.
Single-arm phase 2 trial of 52 patients (44 with synovial sarcoma, 8 with myxoid/round cell liposarcoma) who were HLA-A*02 positive with MAGE-A4-expressing tumours, previously treated with anthracycline or ifosfamide, treated with a single infusion of afamitresgene autoleucel (afami-cel), autologous T cells expressing an affinity-enhanced MAGE-A4-specific T-cell receptor, after lymphodepleting chemotherapy. Primary endpoint was objective response rate.
The response rate was 37% overall and 39% in synovial sarcoma, with a median duration of response of about 12 months. Cytokine release syndrome occurred in about 70% but was mostly low grade. It led to FDA accelerated approval in 2024 (Tecelra), the first TCR-T and the first engineered cell therapy approved for a solid tumour.
Patients with advanced synovial sarcoma, a rare cancer of young adults with few effective drugs, now have an approved cell therapy that produces responses lasting about a year in a substantial minority, if their tissue type and tumour antigen match. It proves that engineered T cells can work against a solid tumour when a good target is present, which had been elusive. It is not a cure for most, requires specialised centres, and only a minority of patients are eligible.
Shares Adaptimmune, Letetresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares Afamitresgene autoleucel, Synovial sarcoma, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares Letetresgene autoleucel, Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Letetresgene autoleucel, MAGE-A4, Afamitresgene autoleucel, Synovial sarcoma.
Shares MAGE-A4, Afamitresgene autoleucel, Synovial sarcoma.
Shares MAGE-A4, Synovial sarcoma, TCR-T cell therapy.
Shares MAGE-A4, Afamitresgene autoleucel, TCR-T cell therapy, Manufacturing cost and time for living and radioactive medicines.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/